SCHEMBL20147439

SCHEMBL20147439

COc1ncc(OC2CCN(C(C)(C)C)C2)cn1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.39
PIK3CD O00329 1/20 0.35
CHRM3 P20309 3/20 0.35
CHRM2 P08172 2/20 0.35
PDE3B Q13370 4/20 0.35
PDE3A Q14432 4/20 0.35
PDE10A Q9Y233 4/20 0.35
CSF1R P07333 1/20 0.34
FLT3 P36888 1/20 0.34
FFAR1 O14842 1/20 0.34
OXTR P30559 1/20 0.33
AVPR1A P37288 1/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22857006 0.82 CHRM4 (0.46) RETPIK3CDCSF1RFLT3OXTR
SCHEMBL20158541 0.82 PIK3CD (0.40) PIK3CDPDE3BPDE3APDE10A
SCHEMBL20069132 0.80 HRH3 (0.46)
SCHEMBL20147438 0.79 RET (0.44) RETPIK3CDCHRM3CSF1RFLT3
SCHEMBL20147444 0.79 RET (0.40) RETPIK3CDPDE3BPDE3APDE10A
SCHEMBL20152045 0.78 HRH3 (0.45)
SCHEMBL8512774 0.78 LPL (0.47) CHRM3CSF1RFLT3
SCHEMBL20147450 0.75 HRH3 (0.51)
SCHEMBL22098606 0.74 CHRM3 (0.55) CHRM3CHRM2
SCHEMBL21004257 0.74 CHRM3 (0.55) CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885PIK3CD 1807/4885CHRM3 2379/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885PIK3CD 1807/4885CHRM3 2379/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RET 1/4885PIK3CD 1807/4885CHRM3 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.